Abstract
Estrogen receptor (ER) is a nuclear hormone receptor and plays an important role in mediating the cellular effects of estrogen. ER can be classified into two receptors: estrogen receptor alpha (ERα) and beta (ERβ), and the former is expressed in 50~80% of breast tumors and has been extensively investigated in breast cancer for decades. Excessive exposure to estrogen can obviously stimulate the growth of breast cancers primarily mediated by ERα, and thus anti-estrogen therapies by small molecules are of concern to clinicians and pharmaceutical industry in the treatment of ERα-positive breast cancers. Although a series of estrogen receptor modulators have been developed, these drugs can lead to resistance and side effects. Therefore, the development of small molecule inhibitors with high target specificity has been intensified. In this pursuit, an integrated computer-aided virtual screening technique, including molecular docking and pharmacophore model screening, was used to screen traditional Chinese medicine (TCM) databases. The compounds with high docking scores and fit values were subjected to ADME (adsorption, distribution, metabolism, excretion) and toxicity prediction, and ten hits were identified as potential inhibitors targeting ERα. Molecular docking was used to investigate the binding modes between ERα and three most potent hits, and molecular dynamic simulations were chosen to explore the stability of these complexes. The rank of the predicted binding free energies evaluated by MM/GBSA is consistent with the docking score. These novel scaffolds discovered in the present study can be used as critical starting point in the drug discovery process for treating ERα-positive breast cancer.
Similar content being viewed by others
References
Wardell SE, Norris JD, McDonnell DP (2019). eLife 8:e44181
Busonero C, Leone S, Klemm C, Acconcia F (2018). Mol Cell Endocrinol 460:229–237
Jordan VC (2018) Arrive. Clin Cancer Res 24:3480–3482
Ashtekar SS, Bhatia NM, Bhatia MS (2018). Steroids 131:14–22
Rondón LM, Villegas V, Rangel N, Sánchez M, Zaphiropoulos P (2016). Int J Mol Sci 17:1357
Thomas C, Gustafsson J (2011). Nat Rev Cancer 11:597–608
Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DM, Greenland JA, Rajan SS, Greene GL (2018). Mol Pharmacol 94:812–822
Tria GS, Abrams T, Baird J, Burks HE, Firestone B, Gaither LA, Hamann LG, Kim S (2018). J Med Chem 61:2837–2864
Xie MS, Zhao H, Liu Q, Zhu YJ, Yin F, Liang YJ, Jiang YH, Wang DY, Hu K, Qin X (2017). J Med Chem 60:8731–8740
Fanning SW, Hodges L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ (2018). Nat Commun 9:2368
Rohatgi N, Blau R, Lower EE (2002). J Womens Health Gend Based Med 11:291–301
Vahrenkamp JM, Yang CH, Rodriguez AC, Almomen A, Berrett KC, Trujillo AN, Guillen KP, Welm BE, Jarboe EA, Janat MM (2018). Cell Rep 22:2995–3005
Liu GF, Sun PM, Dong BH, Sehouli J (2018). Cancer Manag Res 10:6887–6895
Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL (2014). Breast Cancer Res Treat 146:657–667
Rugo HS, JPi D, Im S, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A (2018). Clin Cancer Res 24:2804–2811
Johmura Y, Maeda I, Suzuki N, Wu WW, Goda A, Morita M, Yamaguchi K, Yamamoto M, Nagasawa S, Kojima Y (2018). J Clin Invest 128:5603–5619
Kim S, Wu JY, Birzin ET, Frisch K, Chan W, Pai L, Yang YT, Mosley RT, Fitzgerald PM, Sharma N (2004). J Med Chem 47:2171–2175
Blizzard TA, Dininno F, Morgan JD, Chen HY, Wu JY, Kim S, Chan W, Birzin ET, Yang YT, Pai LY (2005). Bioorg Med Chem Lett 15:107–113
Dykstra KD, Guo LQ, Birzin ET, Chan W, Yang YT, Hayes EC, Dasilva CA, Pai LY, Mosley RT, Kraker B (2007). Bioorg Med Chem Lett 17:2322–2328
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998). Cell 95:927–937
De SC, Bradbury RH, Rabow AA, Norman RA, de Almeida C, Andrews DM, Ballard P, Buttar D, Callis RJ, Currie GS (2015). J Med Chem 58:8128–8140
Scott JS, Bailey A, Davies RDM, Degorce SL, MacFaul PA, Gingell HT, Norman RA, Pink JH, Rabow AA (2015). ACS Med Chem Lett 7:94–99
Li BQ, Ma CF, Zhao XY, Hu ZG, Du TF, Xu XM, Wang ZH, Lin JP (2018). Comput Struct Biotec 16:600–610
Schrödinger (2009). version 9.0; Schrödinger, LLC: New York
Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001). J Phys Chem B 105:6474–6487
Huang XF, Xu P, Cao YJ, Liu L, Song GQ, Xu L (2018). RSC Adv 8:30481–30490
Chen CY (2011). PLoS One 6:e15939
Xu L, Zhang Y, Zheng LT, Qiao CH, Li YY, Li D, Zhen XC, Hou TJ (2014). J Med Chem 57:3737–3745
Walters WP, Stahl MT, Murcko MA (1998). Drug Discov Today 3:160–178
Discovery Studio 2.5 (2009). Accelrys Inc., San Diego
Feng ZW, Hou TJ, Li YY (2012). J Chem Inf Model 52:1005–1014
Feng ZW, Alqarni MH, Yang P, Tong Q, Chowdhury A, Wang L, Xie XQ (2014). J Chem Inf Model 54:2483–2499
Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004). J Comput Chem 25:1157–1174
Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015). J Chem Theory Comput 11:3696–3713
Frisch M, Trucks GW, Schlegel H, Scuseria GE, Robb MA, Cheeseman JR, Montgomery J, Vreven T, Kudin KN, Burant JC (2004) Gaussian 03, revision c. 02, vol 4. Gaussian. Inc., Wallingford, CT
Bayly CI, Cieplak P, Cornell W, Kollman PA (1993). J Phys Chem 97:10269–10280
Peters MB, Yang Y, Wang B, Füsti-Molnár L, Weaver MN, Merz JK (2010). J Chem Theory Comput 6:2935–2947
Darden T, York D, Pedersen L (1993). J Chem Phys 98:10089–10092
Ryckaert JP, Ciccotti G, Berendsen HJ (1977). J Comput Phys 23:327–341
Xu L, Li YY, Sun HY, Li D, Hou TJ (2013). Mol BioSyst 9:2107–2117
Xu L, Sun HY, Li YY, Wang JM, Hou TJ (2013). J Phys Chem B 117:8408–8421
Sun HY, Li YY, Li D, Hou TJ (2013). J Chem Inf Model 53:2376–2389
Shen MY, Zhou SY, Li YY, Pan PC, Zhang LL, Hou TJ (2013). Mol BioSyst 9:361–374
Li L, Li YY, Zhang LL, Hou TJ (2012). J Chem Inf Model 52:2715–2729
Pan PC, Li L, Li YY, Li D, Hou TJ (2013). Antivir Res 100:356–364
Pan PC, Li YY, Yu HD, Sun HY, Hou TJ (2013). J Chem Inf Model 53:997–1006
Kong XT, Pan PC, Li D, Tian S, Li YY, Hou TJ (2015). Phys Chem Chem Phys 17:6098–6113
Sun HY, Li YY, Shen MY, Tian S, Xu L, Pan PC, Guan Y, Hou TJ (2014). Phys Chem Chem Phys 16:22035–22045
Guan Y, Sun HY, Li YY, Pan PC, Li D, Hou TJ (2014). Antivir Res 103:60–70
Chen F, Liu H, Sun HY, Pan PC, Li YY, Li D, Hou TJ (2016). Phys Chem Chem Phys 18:22129–22139
Bai QF, Shen YL, Jin NZ, Liu HX, Yao XJ (2014). BBA-Gen Subjects 1840:2128–2138
Sun HY, Pan PC, Tian S, Xu L, Kong XT, Li YY, Li D, Hou TJ (2016). Sci Rep 6:24817
Sun HY, Chen PC, Li D, Li YY, Hou TJ (2016). J Chem Theory Comput 12:851–860
Hou TJ, Wang JM, Li YY, Wang W (2010). J Chem Inf Model 51:69–82
Hou TJ, Wang JM, Li YY, Wang W (2011). J Comput Chem 32:866–877
Hou TJ, Yu R (2007). J Med Chem 50:1177–1188
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005). J Comput Chem 26:1668–1688
Onufriev A, Bashford D, Case DA (2004). Proteins 55:383–394
Weiser J, Shenkin PS, Still WC (1999). J Comput Chem 20:217–230
Li YP, Peng J, Zhou YH, Li PH, Li YY, Liu XY, Siddique AN, Zhang L, Zuo ZL (2018). Comput Biol Chem 76:53–60
Li YP, Pu YL, Liu H, Zhang L, Liu XY, Li Y, Zuo ZL (2018). J Comput Aid Mol Des 32:901–915
Acknowledgments
This study is supported by the National Science Foundation of China (81803430) and Qing Lan Project and Postgraduate Research and Practice Innovation Program of Jiangsu Province (SJCX18_1051).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Enguang Yu and Yueping Xu are equivalent authors.
Electronic supplementary material
Figure S1
Superposition of eight crystal bound ligands in the ERα activity site. (a) Eight ligands are displayed in sticks and colored green, blue, turquoise, dark green, yellow, orange, pink and red for different ERα crystal structures (PDB ID: 1ERR, 1SJ0, 1XP1, 2IOG, 3ERT, 5AAU, 5FQP and 6B0F). (b) Proteins are shown with ribbon and colored gray. (DOC 1118 kb)
Rights and permissions
About this article
Cite this article
Yu, E., Xu, Y., Shi, Y. et al. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy. J Mol Model 25, 278 (2019). https://doi.org/10.1007/s00894-019-4156-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-019-4156-7